

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the First Amended
Accusation Against:

Leon G. Robb, M.D.

Physician's and Surgeon's
Certificate No. A 28599

Respondent.

Case No. 800-2018-042718


DECISION

The attached Stipulated Surrender of License and Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on November 24, 2021.

IT IS SO ORDERED November 17, 2021.

MEDICAL BOARD OF CALIFORNIA



William Prasifka
Executive Director

1 ROB BONTA
Attorney General of California
2 JUDITH T. ALVARADO
Supervising Deputy Attorney General
3 State Bar No. 155307
California Department of Justice
4 300 South Spring Street, Suite 1702
Los Angeles, CA 90013
5 Telephone: (213) 269-6453
Facsimile: (916) 731-2117
6 *Attorneys for Complainant*

7
8 **BEFORE THE**
9 **MEDICAL BOARD OF CALIFORNIA**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

11 In the Matter of the First Amended Accusation
Against:

Case No. 800-2018-042718

12 **LEON G. ROBB, M.D.**
13 **2270 Canyonback Rd.**
Los Angeles, CA 90049

**STIPULATED SURRENDER OF
LICENSE AND ORDER**

14 **Physician's and Surgeon's Certificate**
15 **No. A 28599,**

16 Respondent.

17
18 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
22 California (Board). He brought this action solely in his official capacity and is represented in this
23 matter by Rob Bonta, Attorney General of the State of California, by Judith T. Alvarado,
24 Supervising Deputy Attorney General.


25 2. Leon G. Robb, M.D. (Respondent) is represented in this proceeding by attorney Mark
26 B. Guterman, Esq., whose address is: LaFollette Johnson, et al., 701 North Brand Boulevard,
27 Suite 600, Glendale, CA 91203.

28 ///

1 License and Order voluntarily, knowingly, and intelligently, and agree to be bound by the
2 Decision and Order of the Medical Board of California.

3
4 DATED: 11-4-21 
5 LEON G. ROBB, M.D.
6 Respondent

7 I have read and fully discussed with Respondent Leon G. Robb, M.D. the terms and
8 conditions and other matters contained in this Stipulated Surrender of License and Order. I
9 approve its form and content.

10 DATED: 11-15-21 
11 MARK B. GUTERMAN, ESQ.
12 Attorney for Respondent

ENDORSEMENT

13 The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted
14 for consideration by the Medical Board of California of the Department of Consumer Affairs.

15 DATED: _____ Respectfully submitted,
16 ROB BONTA
17 Attorney General of California
18 Judith T. Alvarado Digitally signed by
19 Alvarado Date: 2021.11.16
20 JUDITH T. ALVARADO 10:57:41 -08'00'
21 Supervising Deputy Attorney General
22 Attorneys for Complainant

23 LA2021601178
24 Robb-Stipulated Surrender.docx
25
26
27
28

Exhibit A

First Amended Accusation No. 800-2018-042718

1 ROB BONTA
Attorney General of California
2 JUDITH T. ALVARADO
Supervising Deputy Attorney General
3 State Bar No. 155307
California Department of Justice
4 300 South Spring Street, Suite 1702
Los Angeles, CA 90013
5 Telephone: (213) 269-6453
Facsimile: (916) 731-2117
6 *Attorneys for Complainant*

7
8
9 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the First Amended Accusation
13 Against:

Case No. 800-2018-042718

FIRST AMENDED ACCUSATION

14 **LEON G. ROBB, M.D.**
2270 Canyonback Rd.
15 Los Angeles, CA 90049-1177

16 **Physician's and Surgeon's Certificate**
No. A 28599,

17 Respondent.
18

19 **PARTIES**

20 1. William Prasifka (Complainant) brings this First Amended Accusation solely in his
21 official capacity as the Executive Director of the Medical Board of California, Department of
22 Consumer Affairs (Board).

23 2. On or about March 21, 1975, the Medical Board issued Physician's and Surgeon's
24 Certificate Number A 28599 to Leon G. Robb, M.D. (Respondent). That license was in full force
25 and effect at all times relevant to the charges brought herein and will expire on February 28,
26 2022, unless renewed.

27 ///

28 ///

1 JURISDICTION

2 3. This First Amended Accusation is brought before the Board, under the authority of
3 the following laws. All section references are to the Business and Professions Code (Code)
4 unless otherwise indicated.

5 4. Section 2227 of the Code states:

6 (a) A licensee whose matter has been heard by an administrative law judge of
7 the Medical Quality Hearing Panel as designated in Section 11371 of the Government
8 Code, or whose default has been entered, and who is found guilty, or who has entered
9 into a stipulation for disciplinary action with the board, may, in accordance with the
10 provisions of this chapter:

11 (1) Have his or her license revoked upon order of the board.

12 (2) Have his or her right to practice suspended for a period not to exceed one
13 year upon order of the board.

14 (3) Be placed on probation and be required to pay the costs of probation
15 monitoring upon order of the board.

16 (4) Be publicly reprimanded by the board. The public reprimand may include a
17 requirement that the licensee complete relevant educational courses approved by the
18 board.

19 (5) Have any other action taken in relation to discipline as part of an order of
20 probation, as the board or an administrative law judge may deem proper.

21 (b) Any matter heard pursuant to subdivision (a), except for warning letters,
22 medical review or advisory conferences, professional competency examinations,
23 continuing education activities, and cost reimbursement associated therewith that are
24 agreed to with the board and successfully completed by the licensee, or other matters
25 made confidential or privileged by existing law, is deemed public, and shall be made
26 available to the public by the board pursuant to Section 803.1.

27 STATUTORY PROVISIONS

28 5. Section 2234 of the Code, states:

The board shall take action against any licensee who is charged with
unprofessional conduct. In addition to other provisions of this article, unprofessional
conduct includes, but is not limited to, the following:

(a) Violating or attempting to violate, directly or indirectly, assisting in or
abetting the violation of, or conspiring to violate any provision of this chapter.

(b) Gross negligence.

(c) Repeated negligent acts. To be repeated, there must be two or more
negligent acts or omissions. An initial negligent act or omission followed by a
separate and distinct departure from the applicable standard of care shall constitute

1 repeated negligent acts.

2 (1) An initial negligent diagnosis followed by an act or omission medically
3 appropriate for that negligent diagnosis of the patient shall constitute a single
4 negligent act.

5 (2) When the standard of care requires a change in the diagnosis, act, or
6 omission that constitutes the negligent act described in paragraph (1), including, but
7 not limited to, a reevaluation of the diagnosis or a change in treatment, and the
8 licensee's conduct departs from the applicable standard of care, each departure
9 constitutes a separate and distinct breach of the standard of care.

10 (d) Incompetence.

11 (e) The commission of any act involving dishonesty or corruption that is
12 substantially related to the qualifications, functions, or duties of a physician and
13 surgeon.

14 (f) Any action or conduct that would have warranted the denial of a certificate.

15 (g) The failure by a certificate holder, in the absence of good cause, to attend
16 and participate in an interview by the board. This subdivision shall only apply to a
17 certificate holder who is the subject of an investigation by the board.

18 6. Section 2242 of the Code states:

19 (a) Prescribing, dispensing, or furnishing dangerous drugs as defined in Section
20 4022 without an appropriate prior examination and a medical indication, constitutes
21 unprofessional conduct. An appropriate prior examination does not require a
22 synchronous interaction between the patient and the licensee and can be achieved
23 through the use of telehealth, including, but not limited to, a self-screening tool or a
24 questionnaire, provided that the licensee complies with the appropriate standard of
25 care.

26 (b) No licensee shall be found to have committed unprofessional conduct within
27 the meaning of this section if, at the time the drugs were prescribed, dispensed, or
28 furnished, any of the following applies:

(1) The licensee was a designated physician and surgeon or podiatrist serving in
the absence of the patient's physician and surgeon or podiatrist, as the case may be,
and if the drugs were prescribed, dispensed, or furnished only as necessary to
maintain the patient until the return of the patient's practitioner, but in any case no
longer than 72 hours.

(2) The licensee transmitted the order for the drugs to a registered nurse or to a
licensed vocational nurse in an inpatient facility, and if both of the following
conditions exist:

(A) The practitioner had consulted with the registered nurse or licensed
vocational nurse who had reviewed the patient's records.

(B) The practitioner was designated as the practitioner to serve in the absence
of the patient's physician and surgeon or podiatrist, as the case may be.

(3) The licensee was a designated practitioner serving in the absence of the
patient's physician and surgeon or podiatrist, as the case may be, and was in

1 possession of or had utilized the patient's records and ordered the renewal of a
2 medically indicated prescription for an amount not exceeding the original prescription
3 in strength or amount or for more than one refill.

4 (4) The licensee was acting in accordance with Section 120582 of the Health
5 and Safety Code.

6 7. Section 2266 of the Code states:

7 The failure of a physician and surgeon to maintain adequate and accurate
8 records relating to the provision of services to their patients constitutes unprofessional
9 conduct.

10 8. Section 2228.1 of the Code states:

11 (a) On and after July 1, 2019, except as otherwise provided in subdivision (c),
12 the board shall require a licensee to provide a separate disclosure that includes the
13 licensee's probation status, the length of the probation, the probation end date, all
14 practice restrictions placed on the licensee by the board, the board's telephone
15 number, and an explanation of how the patient can find further information on the
16 licensee's probation on the licensee's profile page on the board's online license
17 information Internet Web site, to a patient or the patient's guardian or health care
18 surrogate before the patient's first visit following the probationary order while the
19 licensee is on probation pursuant to a probationary order made on and after July 1,
20 2019, in any of the following circumstances:

21 (1) A final adjudication by the board following an administrative hearing or
22 admitted findings or prima facie showing in a stipulated settlement establishing any
23 of the following:

24 (A) The commission of any act of sexual abuse, misconduct, or relations with a
25 patient or client as defined in Section 726 or 729.

26 (B) Drug or alcohol abuse directly resulting in harm to patients or the extent
27 that such use impairs the ability of the licensee to practice safely.

28 (C) Criminal conviction directly involving harm to patient health.

(D) Inappropriate prescribing resulting in harm to patients and a probationary
period of five years or more.

(2) An accusation or statement of issues alleged that the licensee committed any
of the acts described in subparagraphs (A) to (D), inclusive, of paragraph (1), and a
stipulated settlement based upon a nolo contendere or other similar compromise that
does not include any prima facie showing or admission of guilt or fact but does
include an express acknowledgment that the disclosure requirements of this section
would serve to protect the public interest.

(b) A licensee required to provide a disclosure pursuant to subdivision (a) shall
obtain from the patient, or the patient's guardian or health care surrogate, a separate,
signed copy of that disclosure.

(c) A licensee shall not be required to provide a disclosure pursuant to
subdivision (a) if any of the following applies:

(1) The patient is unconscious or otherwise unable to comprehend the

1 disclosure and sign the copy of the disclosure pursuant to subdivision (b) and a
2 guardian or health care surrogate is unavailable to comprehend the disclosure and
3 sign the copy.

4 (2) The visit occurs in an emergency room or an urgent care facility or the visit
5 is unscheduled, including consultations in inpatient facilities.

6 (3) The licensee who will be treating the patient during the visit is not known to
7 the patient until immediately prior to the start of the visit.

8 (4) The licensee does not have a direct treatment relationship with the patient.

9 (d) On and after July 1, 2019, the board shall provide the following
10 information, with respect to licensees on probation and licensees practicing under
11 probationary licenses, in plain view on the licensee's profile page on the board's
12 online license information Internet Web site.

13 (1) For probation imposed pursuant to a stipulated settlement, the causes
14 alleged in the operative accusation along with a designation identifying those causes
15 by which the licensee has expressly admitted guilt and a statement that acceptance of
16 the settlement is not an admission of guilt.

17 (2) For probation imposed by an adjudicated decision of the board, the causes
18 for probation stated in the final probationary order.

19 (3) For a licensee granted a probationary license, the causes by which the
20 probationary license was imposed.

21 (4) The length of the probation and end date.

22 (5) All practice restrictions placed on the license by the board.

23 (e) Section 2314 shall not apply to this section.

24 FACTUAL ALLEGATIONS

25 9. Respondent is an anesthesiologist. He is not board certified. He has been practicing
26 pain management since 1975. He is currently part of a group practice in Reseda, California.

27 Patient 1¹

28 10. Patient 1 was a 66-year-old male when he first present to Respondent's clinic on June
15, 2016. Between June 21, 2016 and April 3, 2018, Patient 1 was seen twenty-seven times by
Respondent for a chief complaint of lower back pain that radiated to his right leg.

11. At his initial evaluation on June 21, 2016, Patient 1 stated that he underwent epidural
shots by a prior physician, which did not help. He tried physical therapy, which "worsened pain."
He was taking two Norco 5mg, three to four times a week at night and Advil. He reported

¹ The patients are identified in this First Amended Accusation by number to protect their
identities.

1 drinking two glasses of wine two to three time a week. Patient 1 completed paperwork and an
2 initial patient intake form, but he did not sign an opioid or pain contract. Respondent reports that
3 all his patient sign a pain contract before they are prescribed controlled substances.²

4 In this first chart note, Respondent stated that radiologic studies were negative, except an
5 MRI, which demonstrated some disc protrusion and foraminal narrowing, but his symptoms were
6 inconsistent with discogenic radiculopathy. Respondent noted that Patient 1 had significant
7 findings of lumbar degenerative facet disease. On physical exam, the patient complained of pain
8 with deep palpation of the lower back. Respondent rendered a diagnosis of spondylosis of
9 lumbosacral region without myelopathy or radiculopathy; disc degeneration-lumbosacral region;
10 and chronic low back pain without sciatica. The plan was to have the patient return for
11 diagnostic/therapeutic lumbar region intrafacet injections to diagnose significant facet disease.
12 Respondent prescribed Percocet³ 325/10 mg, #90 to Patient 1.

13 12. Patient 1 returned on June 28, 2016, for a right lumbar intrafacet injection at three
14 levels: L3/L4, L4/L5, and L5/S1. The indication for the lumbar injections was persistent pain and
15 that the MRI evidenced facet atrophy.

16 13. Patient 1 returned on July 12, 2016. He denied back pain and his visual analog scale
17 (VAS) [pain scale] score was 6/10. Nevertheless, Respondent performed a second facet nerve
18 block injection.

19 14. Patient 1 returned approximately two weeks later on July 26, 2016. His VAS was
20 5/10, but he complained that he was in continuous pain. Family and work demands increased his
21 lumbar pain. No physical examination was noted. An assessment of spondylosis with back pain
22 and disc [herniation] without radiculopathy was rendered. Respondent prescribed Percocet
23 325/10 mg, #90; Soma⁴ #90; and ibuprofen #90 for Patient 1.

24
25 ² Respondent also acknowledged that his records for the patients discussed in this First
26 Amended Accusation may be incomplete as he has converted from paper charts, to one form of
27 electronic records (EMR), then a second form of EMR in 2018, and portions of charts are or may
28 be missing. Not only are Respondent's medical records for the five patients in various formats,
they are not kept in chronological order, are difficult to follow, and are somewhat illegible.

³ Percocet is a combination of oxycodone, an opioid pain medication, and acetaminophen.
It is a dangerous drug pursuant to section 4022 of the Code.

⁴ Soma is a muscle relaxant and a dangerous drug, pursuant to section 4022 of the Code.

1 15. On August 24, 2016, Respondent performed a right lumbar facet radio-frequency
2 denervation procedure on Patient 1. The patient's medications were refilled on August 23, 2016.
3 He was given Percocet 325/10 mg, #90; Soma 350 mg, #90; and ibuprofen 600 mg, 1 tablet three
4 times per day.

5 16. A left lumbar facet procedure was to be performed on September 22, 2016, but was
6 cancelled. Patient 1's medications of Percocet, Soma and ibuprofen were refilled in the same
7 doses.

8 17. Patient 1 was seen on October 19, 2016. The plan was for a "left facet denervation
9 procedure." His medications were refilled by Respondent.

10 18. The left lumbar facet radio-frequency denervation procedure was performed by
11 Respondent on Patient 1 on October 27, 2016.

12 19. On November 17, 2016, a left transforaminal lumbar epidural was performed by
13 Respondent on Patient 1. Patient 1's medications were refilled by Respondent on November 15,
14 2016.

15 20. The chart entry for December 13, 2016 has only vital signs noted and a list of
16 medications. It appears that the medications were not refills, as it was too soon for refills.

17 21. Patient 1 was seen on January 1, 2017. He was noted to be stable. Patient 1
18 requested a back brace. His medications were refilled by Respondent.

19 22. On January 24, 2017, Respondent performed lumbar facet joint injections under
20 fluoroscopic guidance at levels L3/L4, L4/L5, and L5/S1 on Patient 1. The indication for the
21 procedure was that the patient complained of severe low back pain. He stated he had relief from
22 the denervation procedures. Patient 1 was traveling for work and had increased pain. Patient 1
23 also complained of insomnia. Respondent prescribed Ambien⁵ 10 mg, #30, 1 tablet at bedtime.⁶

24 ///

25 _____
26 ⁵ Ambien is a sedative-hypnotic. It is used to treat insomnia. It is a dangerous drug
pursuant to section 4022 of the Code.

27 ⁶ According to CURES, Patient 1 had been receiving Ambien from another provider. The
28 Controlled Substance Utilization Review and Evaluation System or CURES is a database
maintained by the Department of Justice, which tracks all Schedule II, III, and IV controlled
substances dispensed in California.

1 23. Patient 1 returned on February 22, 2017, reporting that air travel increased nocturnal
2 pain. Patient 1 was noted to be stable. The risk of medications was discussed. Physiotherapy
3 was to be considered. Patient 1's prescriptions for Percocet, Soma, and Ambien were refilled.

4 24. Patient 1 had an appointment for March 22, 2017. He presented for his appointment,
5 but stated he had a family emergency and had to leave. His medications were nevertheless,
6 refilled.

7 25. Patient 1 returned on April 18, 2017. He stated he was leaving for New Orleans. He
8 complained of back pain. No physical examination was performed and no assessment was
9 rendered. Patient 1's medications were refilled by Respondent as follows: Oxycodone 30 mg,
10 #90, 1 tablet every 8 hours; Soma 350 mg, #90, 1 tablet three times per day; Ambien 10 mg, #30,
11 1 tablet at bedtime; and ibuprofen 600 mg #90, 1 tablet three times per day.

12 26. Patient 1 returned on May 17, 2017. He wanted to "go over procedures." No
13 physical examination was performed, no assessment was rendered, however, Patient 1's
14 medications were refilled. Patient 1 was a "no show" for his appointment on May 20, 2017.

15 27. Patient 1 returned on June 15, 2017, for bilateral facet injections. In addition to the
16 facet injections, his medications were refilled.

17 28. Patient 1 returned on July 25, 2017, with complaints of back pain due to stress. The
18 patient was noted to have lumbar instability with increased back pain and elbow strain. An
19 assessment of epicondylitis, back pain, and spondylitis was rendered. Respondent refilled Patient
20 1's medications.

21 29. Patient 1 returned on August 22, 2017, for refills of his medications. His back was
22 noted to be unstable. His medications were refilled.

23 30. Respondent performed facet injections on Patient 1 on September 15, 2017. Patient 1
24 returned on September 19, 2017, stating he got relief from the injections. His medications were
25 refilled.

26 31. Patient 1 returned on November 15, 2017. He reported lower back pain and bilateral
27 elbow pain. An impression of spondylitis with facet atrophy and medial epicondylitis, bilateral,
28 was rendered. Respondent refilled Patient 1's medications. Patient 1 returned the next day,

1 November 16, 2017, complaining of lower back weakness and left leg pain. X-rays showed
2 foraminal stenosis on the left at L4-L5.

3 32. On December 14, 2017, Respondent performed bilateral facet injections on Patient 1
4 for spondylosis with facet atrophy and severe back strain.

5 33. On January 7, 2018, Patient 1 returned for a follow-up. He had complaints of
6 tenderness and instability. The plan was to refill the patient's medications of Percocet, Soma,
7 ibuprofen and Ambien. He was to have bilateral radio-frequency facet injections.

8 34. Patient 1 returned on January 11, 2018, reporting that he got relief from the injections
9 for three weeks. He complained of low back pain, bilateral leg pain and that the medications
10 helped with the pain. His medications were refilled.

11 35. Patient 1 returned to Respondent on April 3, 2018, with complaints of "back pain
12 with facet." The patient had instability. The plan was for radio-frequency denervation of the
13 lumbar region.

14 36. A note dated April 9, 2018 states that C.W., the patient's wife, called. She reported
15 that Patient 1 was an addict and had been hospitalized. He was in court now on a DUI. She also
16 stated Patient 1 takes multiple opiates. She reported that she does not see him in pain. A second
17 note of the same date regarding a second telephone call with Patient 1's wife states that "Wife
18 says he is a drug addict, has been in rehab in the past. Got drugs from different sources. Has
19 been in court for DUI."

20 37. Patient 1 did not return to Respondent's office.

21 **Patient 2**

22 38. Patient 2, was a 31-year-old female at the time of her first visit with Respondent on
23 March 15, 2017. Between March 15, 2017 and February 3, 2021, Patient 2 saw Respondent
24 twenty-nine times for a chief complaint of back pain that radiated down to her right leg.

25 39. At her initial visit with Respondent, Patient 2 reported pain in her right leg, which
26 was severe and idiopathic at onset. She had difficulty with standing. A diagnosis after a CT scan
27 from a prior provider was sciatica. She had limited pre-op therapy and no epidural treatment.
28 Patient 2 underwent lumbar disc surgery, which provided relief for about 1 year with recurrence.

1 Patient 2 had a second surgery by the same surgeon, followed by physiotherapy, ibuprofen, and
2 hydrocodone. Her pain persisted and recently became severe, followed by an emergency room
3 visit where Patient 2 was given the pain medication Norco, which did not provide sufficient relief.
4 She was referred to Respondent for evaluation and treatment. Patient 2 stated that a friend gave
5 her oxycodone 30 mg, which ameliorated her pain.

6 Patient 2 described her pain as horrible to excruciating which increased with activity,
7 including walking, sitting, and standing. Dampness and cold weather created more pain as did
8 sexual activity. Pain in her low back was burning, with tingling and aching down the right leg to
9 the foot. A physical examination demonstrated weakness to the right lower extremity. Deep
10 tendon reflexes were hypoactive. The right anterior thigh and calf demonstrated decreased
11 sensation to pin scratch and vibration. There was lumbar tenderness from L3 to sacrum. Sciatic
12 notch tenderness was noted on the right. An impression of post laminectomy syndrome, right
13 lumbar radiculopathy was rendered. The plan was for a caudal epidural with epidurogram under
14 fluoroscopy. The risks and benefits were explained.

15 40. The epidurogram was scheduled for April 6, 2017, but the patient did not show. She
16 presented on May 3, 2017, and underwent a caudal epidural, which was noted as uncomplicated.
17 Respondent prescribed oxycodone 10 mg, #90, take 1-3 tablets per day PRN (as needed) for pain
18 and Neurontin⁷ 300 mg, #90, 1 tablet, three times per day (tid). The medications were listed as a
19 "refill," however, this was the first time Respondent prescribed medications for Patient 2.

20 41. Between May 4, 2017 and May 16, 2017, Patient 2's husband called advising that
21 Patient 2 was in a lot of pain, suffering from a headache. He repeatedly requested a prescription
22 for Xanax. Patient 2 presented on May 17, 2017. She was requesting an increase in her dose of
23 oxycodone. Patient 2 stated the injection only worked for 2 days and after that the pain returned.
24 Prozac⁸ 20 mg, #30, was added to her medications. Patient 2 did not show for her next
25

26
27 ⁷ Neurontin is a anti-epileptic medication used to treat seizures and nerve pain. It is a
dangerous drug pursuant to section 4022 of the Code.

28 ⁸ Prozac is a Selective Serotonin Reuptake Inhibitor (SSRI). It is used to treat depression.
It is a dangerous drug pursuant to section 4022 of the Code.

1 appointment of May 30, 2017. She was seen on June 8, 2017, and received a refill of her
2 medications. No physical examination was performed and no assessment was rendered.

3 42. A caudal epidural was performed on Patient 2 on June 20, 2017. She returned on July
4 12, 2017, for an episodic check. She reported lower back pain of 9/10. No physical examination
5 was performed and no assessment was rendered. Respondent refilled her prescriptions.

6 43. Patient 2 did not show for her August 2, 2017 appointment. A note dated August 16,
7 2017, states that Patient 2 attempted to fill a lost prescription from June 8, 2017, which had been
8 called in. Patient 2 then did not show up for or cancelled her next two scheduled appointments.
9 Respondent did not recognize Patient 2's behavior as a red flag for drug seeking or diversion.

10 44. Patient 2 underwent another caudal epidural on September 13, 2017. Her medications
11 were also refilled and Xanax⁹ was added to her regimen: Neurontin 300 mg #90, tid; oxycodone
12 10 mg, #90, 1-3 tablets a day PRN; Prozac 20 mg, #30; and Xanax 2 mg. On September 18,
13 2017, the patient's husband called and stated the patient was in pain and that the procedure did
14 not work. Patient 2 cancelled her October 4, 2017 appointment. Respondent noted that the
15 patient's husband may be stealing her medications.

16 45. At her November 29, 2017 visit, Patient 2 reported that she had lower back pain and
17 bilateral lower extremity pain. A limited examination was performed and an assessment of failed
18 back surgery times two was rendered. Respondent increased Patient 2's medication to Neurontin
19 300 mg, #90, tid; oxycodone 10 mg, #120, increased to every 6 hours prn pain; Prozac 20 mg
20 #30; and Xanax 2 mg, #60, 1 tablet twice a day (bid).

21 46. The note for January 3, 2018 shows "N/S" or no show. However, a "SOAP"¹⁰ note is
22 prepared, appearing as if Patient 2 presented for the visit. Her medications were increased as
23

24
25 ⁹ Xanax is a benzodiazepine anxiolytic. It is a dangerous drug pursuant to section 4022 of
26 the Code. On August 31, 2016, the Federal Drug Administration issued a Black Box Warning
27 regarding the combined prescribing of opioids and benzodiazepines that depress the central
28 nervous system and has resulted in serious side effects, including slowed or difficult breathing
and death.

¹⁰ The SOAP Note is an acronym for Subjective, Objective, Assessment and Plan. It is a
method of organized documentation for healthcare providers.

1 follows: Oxycontin¹¹ 20 mg, #60, 1 tablet every 12 hours; Xanax 2 mg, #60, bid; Prozac 20 mg,
2 #30; oxycodone 10 mg, #90; and Neurontin 300 mg tid #90.

3 47. The patient signed a pain contract on January 10, 2018.

4 48. On February 8, 2018, Patient 2 reported that her insurance did not pay for oxycontin.
5 She requested a change in medications for control of back pain and otherwise poor health. A
6 limited physical exam was performed showing numbness of the lower back and weakness in her
7 legs. An assessment of status-post two spine surgeries was rendered. Her medication was
8 changed to: Xanax 2 mg, #60, bid; Prozac 20 mg, #30; oxycodone 10 mg, #90, and Neurontin 300
9 mg #90.

10 49. At her next appointment of March 8, 2018, Patient 2 complained of pain at level of
11 10/10. She wanted to review her medications. Respondent increased her oxycodone 10 mg to 1
12 tablet every 6 hours, #120. Five days later, on March 13, 2018, the patient called stating she
13 wanted to go on Percocet. She reported her pain as a 10/10. Respondent did not appreciate this
14 call as a red flag for drug seeking behavior or diversion.

15 50. At Patient 2's next visit on April 5, 2018, Respondent again increased her pain
16 medication to: oxycodone 20 mg, #90, 1 tablet every 8 hours or ½ tablet every 4 hours. A limited
17 physical examination was positive for radiculopathy, straight leg raise testing was positive, a
18 tender back, a scar, and numbness were noted. No assessment was rendered. An epidural was
19 planned.

20 51. From October 18, 2018 to January 17, 2020, Patient 2 was seen by different
21 providers. Patient 2's opioid dosing was being tapered. She demanded her care be returned to
22 Respondent.

23 52. Patient 2 returned to Respondent's care on February 20, 2020. He placed her back on
24 Xanax 0.5 mg, tid, although a prior note by Patient 2's prior provider dated January 17, 2020
25 stated that she had not had Xanax since October 15, 2019. Respondent refilled her Percocet and
26 muscle relaxant, tizanidine.

27 ¹¹ Oxycontin is an extended release form of the medication, oxycodone. It is a dangerous
28 drug pursuant to section 4022 of the Code.

1 53. Beginning on March 18, 2020, Respondent provided care to Patient 2 via
2 telemedicine due to the COVID-19 pandemic. On this visit, he started her on indomethacin¹² 50
3 mg, tid (no amount listed). Telemedicine visits were held on June 2, 2020 and July 3, 2020. At
4 the July 3, 2020 visit, Respondent placed Patient 2 back on oxycodone 20 mg, every 8 hours.

5 54. Respondent restarted Percocet 10-325 mg, #120, every 6 hours, along with
6 oxycodone 20 mg, #90, every 8 hours, prn as needed for pain, on October 21, 2020.

7 55. Respondent's last encounter noted in the chart is dated February 3, 2021. At that
8 visit, a right transforaminal epidural was performed at L4/L5 and L5/S1. Patient 2 was continued
9 on Xanax 2 mg, #60, bid; indomethacin 50 mg, #90; oxycodone 20 mg, #90 1 tablet every 8 hours
10 prn pain; Percocet 10-325 mg, #120, 1 tablet every 6 hours prn pain; tizanidine 4 mg, #30; and
11 Neurontin 300 mg, #90, tid.

12 **Patient 3**

13 56. Patient 3 was a 33-year-old male at the time of his first visit with Respondent on
14 March 19, 2020. He is noted to be the husband of Patient 2. Respondent has only one chart entry
15 for Patient 3, a note dated March 19, 2020.

16 57. According to CURES, Respondent prescribed Percocet, Norco and Xanax for Patient
17 3 from March 18, 2017 through January 18, 2018. There are no chart notes to correspond to this
18 prescribing.

19 58. Patient 3's chart indicates that he was seen by different providers on November 12,
20 2019 and December 9, 2019. When he was seen by Respondent on March 19, 2020, he
21 complained of neck and back pain. Patient 3 stated that he had not seen Respondent for almost 2
22 years. Patient 3 stated while he had been in prison, he had chronic pain that caused sleeplessness,
23 difficulty walking, and lower extremity pain. He also had an excision of cyst of the pituitary
24 gland and was taking steroids. Patient 3 desired to get back on a regimen to control his back pain.
25 Respondent rendered an assessment of backache, cervicalgia, pituitary cyst, pituitary disorder,
26 insulin-dependent diabetic with neurological complications-long term, lumber disc disorder,

27 _____
28 ¹² Indomethacin is a nonsteroidal anti-inflammatory medication used to relieve pain,
swelling and joint stiffness.

1 adjustment reaction with anxiety and depression. He prescribed Percocet 325/10 mg, #60, 1
2 tablet, bid; and Xanax 0.5 mg, #90, tid, for Patient 3. Respondent did not see Patient 3 again,
3 according to the chart notes.

4 59. Patient 3 was discharged from the group's practice on August 20, 2020, by another
5 provider for disruptive behavior after he was denied Percocet.

6 **Patient 4**

7 60. Patient 4 was a 28-year-old female when she first treated with Respondent on August
8 11, 2015. She has had forty-seven visits with Respondent from August 11, 2015 through January
9 13, 2021, and remains his patient.

10 61. Patient 4 was referred to Respondent by another physician for pain management. She
11 was taking oxycodone 30 mg, #90, as needed for pain, and reported that sometimes she took 4
12 pills a day. Her onset of pain was idiopathic in 2012, but she had a motor vehicle accident in
13 2013. Patient 4 stated she was in constant excruciating low back pain, spreading to the posterior
14 lateral aspect of the leg down to the foot. Her back pain was sharp and throbbing. Her anterior
15 thigh tingled, ached and throbbed. Her left knee pain was sharp. There was also an indication of
16 left arm tingling, throbbing and aching. Notes from a chiropractor indicate lumbar spine facet
17 syndrome, spine strain/sprain and sacroiliac joint sprain/strain. Patient 4 denied the use of
18 alcohol or illicit drugs.

19 A physical exam showed mild antalgic gait, favoring the left leg. Weakness was
20 demonstrated on repeated toe-raise testing on the left. A positive bowstring sign on the left was
21 noted. Extension in the prone position produced left anterior thigh pain. Decreased sensation to
22 scratch and tuning fork over thigh, knee, and lateral leg to the ankle was noted. The medial
23 aspect of the left foot had decreased sensation. There was no atrophy or wasting. The lungs were
24 clear, the heart had a regular sinus rhythm with no murmurs. Imaging studies and an MRI from
25 August 16, 2013 were reviewed and noted as negative.

26 An impression of persistent lumbar symptomatology with lower extremity radiculopathy
27 was rendered. Respondent noted, "Negative MRI, but may benefit from epidural therapy. Refer
28 for orthopedic consult. Alternative is further physical therapy." Respondent prescribed

1 Oxycontin 30 mg, tid. He noted that Patient 4 was reluctant to try Neurontin. Her medication
2 was changed to oxycodone on August 15, 2015.

3 62. Patient 4 continued to treat with Respondent about once a month. Her medication
4 remained unchanged. She was started on Neurontin 300 mg, # 90, tid, on May 18, 2016. She
5 received her first steroid injection on October 4, 2016.

6 63. On February 23, 2017, Patient 4 began to complain of knee swelling and arm pain.
7 On June 16, 2017, she underwent an epidural block with epidurography. Patient 4 continued to
8 treat with Respondent approximately every month and remained on the same medications.
9 Respondent noted that Patient 4 could not undergo epidurals under local anesthesia, they must be
10 performed in the hospital.

11 64. On March 12, 2018, Patient 4 stated her ex-boyfriend hit her and now she was having
12 a hard time hearing out of her right ear. Respondent refilled her prescriptions for oxycodone 30
13 mg, #90, tid; Neurontin 300 mg, #90, tid; and started Soma 350 mg, #90, tid.

14 65. On May 10, 2018, Patient 4 underwent an epidural block and epidurography. She
15 continued to treat with Respondent monthly, receiving the same medications. On November 8,
16 2018, she reported opioid induced constipation. She remained on the same medications with
17 Movantik¹³ 25 mg, #25, added to address the constipation issue.

18 66. On December 10, 2018, Patient 4 complained of left leg pain and back pain. She
19 reported that she had struck her left knee and had swelling and pain. Her weight bearing was
20 affected due to the knee issue. On examination, her knee had tenderness with no swelling and it
21 was difficult to bend. An assessment of left knee injury, left knee pain, left knee sprain, lumbar
22 disc disease with radiculopathy, lumbago due to displacement of intervertebral disc, constipation
23 due to pain medication-drug induced constipation, was rendered. She was continued on the same
24 medications.

25 ///

26 ///

27

28 ¹³ Movantik is a prescription medication used to treat opioid induced constipation in adults
with chronic, non-cancer pain.

1 67. On January 19, 2019, Patient 4 continued to complain of the left knee issues and her
2 back pain and tenderness persisted. Her medications were continued and Xanax 0.5 mg, #90, 1-2
3 tablets, bid, was added to her regimen.

4 68. Patient 4 continued to see Respondent monthly. Her medications continued. On July
5 24, 2019, Patient 4 reported "recent ER visits" for severe extremity pain and spasms. She stated
6 she received intramuscular steroids and an opioid injection. Her symptoms resolved in several
7 days. Respondent refilled her medications and added a Medrol Dosepak¹⁴ to her medication
8 regimen.

9 69. Patient 4 continued to see Respondent monthly and received the same medications,
10 including the Medrol Dosepak, up to September 18, 2019. On November 6, 2019, she underwent
11 a lumbar epidural with epidurogram under conscious sedation. On February 19, 2020 Patient 4
12 underwent a genicular nerve block of left knee. She was to return for "possible
13 radiofrequency/denervation funicular nerves".

14 70. From March 19, 2020 through October 28, 2020 Respondent held telephone or
15 telehealth visits with Patient 4 either monthly or every other month. Patient 4 would describe her
16 symptoms and Respondent would refill her medications.

17 71. On November 18, 2020, Patient 4 presented for an in-person visit with Respondent.
18 Her lumbar pain persisted with left radiculopathy. On examination she had lumbar tenderness,
19 restricted motion with flexion, extension, rotation and side bending. An assessment of left knee
20 pain, knee ankylosis, degenerative arthritis of left knee, lumbar disc disease with radiculopathy-
21 intervertebral disc disorders with radiculopathy, lumbar region, was rendered. Respondent noted
22 that Patient 4 was dependent on pain medication and had drug induced constipation. Respondent
23 changed Patient 4's medications to Xanax to 2 mg, #90, 1 tablet tid; Soma 350 mg, #90, 1 tablet
24 tid; Neurontin 300 mg, #120, 1 capsule every 6 hours; Movantik 25 mg, #30, 1 tablet every
25 morning; oxycodone 30 mg, #120, 1 tablet every 6 hours.

26 ///

27 _____
28 ¹⁴ A Medrol Dosepak is a tapering dose of methylprednisolone, used to treat inflammatory conditions. It is a dangerous drug pursuant to section 4022 of the Code.

1 72. Respondent resumed telehealth visits with Patient 4 on December 22, 2020 and
2 January 13, 2021. She was continued on the same medications.

3 **Patient 5**

4 73. Patient 5 was 28-years-old when she first presented to Respondent's office on July
5 27, 2016. Between July 28, 2016 and January 10, 2019, Patient 5 had twenty-seven visits with
6 Respondent. Between July 27, 2016 and May 8, 2017, Patient 5 received twenty-nine
7 prescriptions for tramadol, 50 mg. Patient 5's tramadol 50 mg dose started at #60 tablets. It was
8 increased to #90 tablets on March 24, 2017, then lowered to #60 tablets on April 10, 2017 (but,
9 this was an early refill). Her dose was then increased to #90 tablets on July 25, 2017, where it
10 remained until December 13, 2017. On December 13, 2017 the dose was increased to #240
11 tablets. The last refill reflected on CURES was on May 8, 2018, for #240 tablets.

12 74. When Patient 5 began treating with Respondent she was in training to become a
13 registered nurse. She reported that she hurt her back moving a patient in 2015. However, she had
14 a seven-year history of episodic pain secondary to very active dancing. Her pain was constant
15 and variable from uncomfortable to horrible. It was relieved with an application of topical cream,
16 lying, or sitting. Her pain was worse with pulling, lifting, bending, turning, or twisting. She also
17 complained of dysmenorrhea. Patient 5 stated that she took naproxen and ibuprofen and was
18 prescribed tramadol and Flexeril.¹⁵

19 On examination, she was in no distress, was oriented, had no indication of somatization in
20 the Wahler Physical System Inventory test. She had no indication of depression. Repeated toe
21 raises did not induce fatigue. Supine straight leg raising caused low back pain. Prone extension
22 was positive. Tenderness to deep palpation of the lumbar paraspinals was present. Deep tendon
23 reflexes were satisfactory. Reactions to vibration and pin scratch were decreased on the right
24 calf. Straight-leg raising did not evoke positive sciatic stretch signs. No atrophy or wasting of
25 lower extremities was noted. Palpation of the abdomen was negative for rebound or tenderness.
26 The heart had a regular sinus rhythm with no murmur. The lungs were clear. An assessment of

27 _____
28 ¹⁵ Flexeril or cyclobenzaprine is a skeletal muscle relaxant. It is used to treat muscle spasms. It is a dangerous drug pursuant to section 4022 of the Code.

1 spondylosis with radiculopathy, back pain, and dysmenorrhea was rendered. Respondent
2 prescribed Motrin 600 mg, #120, 1 tablet four times per day; tramadol 50 mg, #60, 2 tablets twice
3 a day (bid); and Flexeril 5 mg, #60, bid.

4 75. On December 14, 2016, Respondent noted that Patient 5 completed her nursing
5 program. Her diagnosis was spondylosis with radiculopathy. She remained on tramadol and
6 Flexeril. On March 22, 2017, Respondent increased the dose of tramadol to #90 tablets and
7 Flexeril to #90. Motrin was discontinued as it upset the patient's stomach.

8 76. Patient 5 continued to see Respondent monthly for pain medication refills. On
9 February 8, 2018, the patient requested to add Motrin back to her medication regimen. Her
10 tramadol was increased to #240 tablets as well. She continued on this dose for the next six
11 months. On August 23, 2018, cyclobenzaprine 10 mg, #90, three times a day, was added to
12 Patient 5's medication regimen.

13 77. On September 26, 2018, Respondent noted "no finding" on physical the examination.
14 Nevertheless, he prescribed tramadol 50 mg, #90 for Patient 5. She is continued on Flexeril and
15 tramadol #90 tablets through October 31, 2018. On November 21, 2018, Patient 5 complained of
16 back and leg pain. On examination, she had mild antalgic gait, lower extremity pain,
17 radiculopathy, and neurological findings were positive with back tenderness. An assessment of
18 spondylosis of the lumbosacral region without myelopathy or radiculopathy, lumbago with
19 sciatica right side, and dysmenorrhea was rendered. Respondent increased Patient 5's dose of
20 tramadol 50 mg to #240 pills again.

21 78. Patient 5's last visit with Respondent was on January 10, 2019. He noted that Patient
22 5 was deteriorating. He recommended a lumbar steroid injection. Respondent refilled the
23 tramadol 50 mg, #240, and restarted Flexeril 10 mg, #30, 1 tablet at bedtime.

24 **Standard of Care**

25 79. The standard of care for radio-frequency ablation for the medial branches of the
26 posterior primary ramus require a thorough physical examination pointing to the diagnosis of
27 facet syndrome. Imaging should correlate appropriately. A diagnostic block, including a pain
28 diary, showing more than 80% relief on repeated blocks is also standard of care. If the diagnostic

1 block and objective physical examination findings support the assessment, then destructive
2 lesioning of the medial branch can be offered to the patient.

3 80. The standard of care for epidural injections includes a verifiable nerve root lesion on
4 imaging and/or nerve conduction studies. No more than four injections a year are indicated.
5 Appropriate patient response includes relief lasting at least three weeks between injections.
6 Monitoring and recording of potential side effects from repeated exposures to off-label steroids
7 should be indicated in the record.

8 81. A history and physical, including a complete intake must be performed at the outset
9 when prescribing controlled substances. Informed consent for treatment with controlled
10 substances must be obtained from the patient. This may include a "pain agreement." Risks and
11 benefits of treatment with controlled substances must be explained. Prior to prescribing opioids,
12 there must be an identifiable, documented diagnosis causing chronic pain in the patient. Opioid
13 prescriptions must not be considered an ongoing ever-escalating therapeutic plan. Rather, it
14 should be a part of a comprehensive treatment plan that includes referrals to subspecialists,
15 including fellowship trained pain management specialists, addiction specialists, psychiatrists,
16 physical therapists, and surgeons, when appropriate.

17 82. Treatment objectives, including specifically identifiable pain management goals must
18 be clearly identified in the rendering of the provider's plan. Periodic review by the provider of
19 the patient's response to treatment should be documented in the treatment plan and adjusted
20 accordingly. A clear plan of action by the physician must be legible and logical. Treatment
21 objectives should be clearly delineated and substantiated in the plan section. Response to therapy
22 must be clearly indicated in the treatment plan. If there is a failure to respond adequately to the
23 stated goals of treatment, then it is incumbent on the prescriber to taper and stop the opioid
24 prescriptions.

25 83. In addition to regular assessment of efficacy of treatment, assessment of possible
26 diversion is incumbent on the prescriber. Regular drug screens (urine or other), CURES review,
27 or other objective means of review must be conducted. If a urine drug screen identifies illicit
28 substances or if diversion is suspected, a frank discussion must be had and appear in the patient's

1 record. If analysis indicates diversion, prescriptions for scheduled medications must be stopped.
2 Suspicion for use of illicit substances or misuse of controlled substances requires referral to an
3 addiction specialist for patient management. It is problematic to prescribe to a known addict
4 without the involvement of a sub-specialist. Continued unexplained increases in dose
5 requirements without concurrent improvement in quality-of-life and participation in valued
6 activities should spur a referral to a pain management specialist for an opinion to help guide
7 treatment.

8 84. There is unequivocal peer-reviewed literature that demonstrates that the chronic use
9 of opioid medications are associate with increased depression, opioid tolerance, addiction
10 potential, dependence, decreased immune function, risk to the fetus in a pregnant patient,
11 significantly abnormal endocrine function, including osteoporosis and fractures, and opioid
12 induced hyperalgesia. These negative effects should be discussed with the patient and noted in an
13 informed consent document. In addition, there is relative contraindication to co-prescribe
14 benzodiazepine medications and opioids concurrently given the risk of respiratory depression and
15 death.

16 85. A good faith examination consists of vital signs. Also, a visual analog scale for pain
17 assessment is advocated in the absence of any objectifiable scan to indicate the patient's pain; it
18 should also be documented. A focused system evaluation is indicated. Copying and pasting from
19 one visit to another may indicate that an examination may not have been performed.

20 86. The failure to intervene when life is at stake represents the most important standard of
21 care followed by all physicians. When evidence of self-harm or addiction is witnessed, there is a
22 duty to intervene. The physician should stop the prescribing, taper the prescriptions, provide
23 appropriate psychiatric referral and involve family members to the extent permitted by the
24 patient.

25 ///

26 ///

27 ///

28 ///

1 **FIRST CAUSE FOR DISCIPLINE**

2 **(Gross Negligence)**

3 87. Respondent Leon G. Robb, M.D. is subject to disciplinary action under section 2234,
4 subdivision (b) of the Code, in that his care and treatment of three patients was grossly negligent.
5 The circumstances are as follows:

6 **Patient 1**

7 88. The facts and allegations set forth in paragraphs 10 through 37 and 79 through 86, are
8 incorporated herein, as if fully set forth.

9 89. Respondent was grossly negligent in his care and treatment of Patient 1 in that:

10 A. Many of his handwritten notes do not include an analysis of the patient's
11 response to opioid therapy, including addressing quality of life, goals or compliance to therapy.

12 B. Physical examinations do not include vital signs or a visual analog pain scale
13 score.

14 C. There was no attempt to check for diversion, there was no urine drug screening,
15 CURES was not checked, and a pill count was never conducted.

16 D. His continued prescribing of opioid therapy was not justified.

17 **Patient 2**

18 90. The facts and allegations set forth in paragraphs 38 through 55 and 79 through 86, are
19 incorporated herein, as if fully set forth.

20 91. Respondent was grossly negligent in his care and treatment of Patient 2 in that:

21 A. There was no opioid contract until January 1, 2018, a year after Respondent
22 started prescribing opioids for Patient 2.

23 B. There was no urine drug screening conducted, CURES was not checked, and
24 there were no pill counts to ensure there was no diversion of medication.

25 C. There was no associated physical examination or intermittent plan in response
26 to therapy or an assessment of effectiveness of therapy.

27 ///

28 ///

1 D. There were multiple red flag findings, including the illegal use of medication by
2 the patient at her first visit and the patient's husband repeatedly calling and requesting controlled
3 substances.

4 E. The continued prescription of opioid therapy was an extreme departure from the
5 standard of care.

6 **Patient 4**

7 92. The facts and allegations set forth in paragraphs 60 through 72 and 79 through 86, are
8 incorporated herein, as if fully set forth.

9 93. Respondent was grossly negligent in his care and treatment of Patient 4 in that:

10 A. There were no urine drug screen results in the patient's chart, CURES was not
11 checked, and there were no pill counts to check for medication diversion.

12 B. There were no associated physical examinations, no intermittent plans in
13 response to therapy, and no assessment of the effectiveness of therapy.

14 C. Morphine Milligram Equivalent (MME)¹⁶ dosing exceeded 90 mg when Patient
15 4 was given up to 120 mg of MME per day, without additional documentation regarding
16 medication effectiveness and ultimate therapy goals.

17 D. The continued prescription of opioid therapy was an extreme departure from the
18 standard of care.

19 **SECOND CAUSE FOR DISCIPLINE**

20 **(Repeated Negligent Acts)**

21 94. Respondent Leon G. Robb, M.D. is subject to disciplinary action under section 2234,
22 subdivision (c) of the Code, in that his care and treatment of four patients was negligent. The
23 circumstances are as follows:

24 **Patient 1**

25 95. The facts and allegations set forth in paragraphs 10 through 37 and 79 through 86, are
26 incorporated herein, as if fully set forth.

27 _____
28 ¹⁶ MME is a numerical standard against which most opioids can be compared. It is used
to determine how different opioids relate to each other, using morphine as the standard.

- 1 96. Respondent was negligent in his care and treatment of Patient 1 in that:
- 2 A. Many of his handwritten notes do not include an analysis of the patient's
- 3 response to opioid therapy, including addressing quality of life, goals or compliance to therapy.
- 4 B. Physical examinations do not include vital signs or a visual analog pain scale
- 5 score.
- 6 C. There was no attempt to check for diversion, there was no urine drug screening,
- 7 CURES was not checked, and a pill count was never conducted.
- 8 D. His continued prescribing of opioid therapy was not justified.
- 9 E. He failed to conduct a physical examination to support a diagnosis of lumbar
- 10 facet syndrome. An MRI showed normal facets at L3, L4, and L5, which were the targets of
- 11 repeated destructive procedures.
- 12 F. There does not appear to be diagnostic blocks recorded or a response to the
- 13 procedures recorded, prior to a decision to move ahead to nerve destruction.
- 14 G. There was no record of informed consent from the patient.

15 **Patient 2**

16 97. The facts and allegations set forth in paragraphs 38 through 55 and 79 through 86, are

17 incorporated herein, as if fully set forth.

18 98. Respondent was negligent in his care and treatment of Patient 2 in that:

- 19 A. There was no opioid contract until January 1, 2018, a year after Respondent
- 20 started prescribing opioids for Patient 2.
- 21 B. There was no urine drug screening conducted, CURES was not checked, and
- 22 there were no pill counts to ensure there was no diversion of medication.
- 23 C. There was no associated physical examination or intermittent plan in response
- 24 to therapy or an assessment of effectiveness of therapy.
- 25 D. There were multiple red flag findings, including the illegal use of medication by
- 26 the patient at her first visit and the patient's husband repeatedly calling and requesting controlled
- 27 substances.

28 ///

1 E. The continued prescription of opioid therapy was a departure from the standard
2 of care.

3 F. There does not appear to be a physical examination which supports a diagnosis
4 of lumbar radiculopathy.

5 G. MRI imaging fails to show any nerve root impingement.

6 H. Indications for repeated caudal epidural injections is "laminectomy." This is
7 not an accepted diagnosis which warrants an epidural injection.

8 **Patient 4**

9 99. The facts and allegations set forth in paragraphs 60 through 72 and 79 through 86, are
10 incorporated herein, as if fully set forth.

11 100. Respondent was negligent in his care and treatment of Patient 4 in that:

12 A. There were no urine drug screen results in the patient's chart, CURES was not
13 checked, and there were no pill counts to check for medication diversion.

14 B. There were no associated physical examinations, no intermittent plans in
15 response to therapy, and no assessment of the effectiveness of therapy.

16 C. Morphine Milligram Equivalent (MME) dosing exceeded 90 mg when Patient 4
17 was given up to 120 mg of MME per day, without additional documentation regarding medication
18 effectiveness and ultimate therapy goals.

19 D. The continued prescription of opioid therapy was a departure from the standard
20 of care.

21 E. There does not appear to be a physical examination supporting a diagnosis of
22 lumbar radiculopathy or facet disease. MRI imaging is relatively normal in reference to the age
23 of the patient. Two independent consultants, an orthopedist and a chiropractor, indicated that
24 there were no significant spinal lesions requiring treatment other than rehabilitation.

25 F. Repeated epidural and facet injections were not indicated.

26 **Patient 5**

27 101. The facts and allegations set forth in paragraphs 73 through 86, are incorporated
28 herein, as if fully set forth.

1 102. Respondent was negligent in his care and treatment of Patient 5 in that:

2 A. He failed to conduct a good faith physical examination at subsequent visits and
3 there was no appropriate response to therapy.

4 B. He failed to evaluate the potential for abuse of tramadol by the patient. The
5 continued use of Flexeril in excess of ten days was questionable, as it is recommended for short-
6 term use.

7 C. The continued prescribing of controlled substance medications is negligence.

8 **THIRD CAUSE FOR DISCIPLINE**

9 **(Furnishing Dangerous Drugs without a Medical Examination)**

10 103. Respondent Leon G. Robb, M.D. is subject to disciplinary action under section 2242
11 of the Code, in that he prescribed dangerous drugs to five patients without proper medical
12 examinations and without medical indication. The circumstances are as follows:

13 104. The facts and allegations set forth in paragraphs 10 through 86, are incorporated
14 herein, as if fully set forth.

15 105. Respondent prescribed dangerous drugs to Patients 1 through 5, including opioid
16 medications, without conducting complete examinations and without medical indication, in
17 violation of section 2242 of the Code.

18 **FOURTH CAUSE FOR DISCIPLINE**

19 **(Failure to Maintain Adequate and Accurate Medical Records)**

20 106. Respondent Leon G. Robb, M.D. is subject to disciplinary action under section 2266
21 of the Code, in that he failed to maintain adequate and accurate medical records for Patients 1
22 through 5. The circumstances are as follows:

23 107. The facts and allegations set forth in paragraphs 10 through 86, are incorporated
24 herein, as if fully set forth.

25 ///

26 ///

27 ///

28 ///


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate Number A 28599, issued to Leon G. Robb, M.D.;
2. Revoking, suspending or denying approval of Leon G. Robb, M.D.'s authority to supervise physician assistants and advanced practice nurses;
3. Ordering Leon G. Robb, M.D., if placed on probation, to pay the Board the costs of probation monitoring;
4. If disciplined, ordering Leon G. Robb, M.D. to disclose his discipline to patients as required by section 2228.1 of the Code; and
5. Taking such other and further action as deemed necessary and proper.

DATED: APR 29 2021


WILLIAM PRASIFKA
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

LA2021601178